Affiliation:
1. Medical University of Vienna
2. University of Vienna
3. Aarhus University Hospital
4. University of Graz
Abstract
Abstract
Background
E. coli O83 (Colinfant Newborn) is a Gram-negative (G-) probiotic bacterium used in the clinic. When administered orally, it reduces allergic sensitisation but not allergic asthma. Intranasal administration offers a non-invasive and convenient delivery method. This route bypasses the gastrointestinal tract and provides direct access to the airways, which are the target of asthma prevention. G- bacteria such as E. coli O83 release outer membrane vesicles (OMVs) to communicate with the environment. Here we investigate whether intranasally administered E. coli O83 OMVs (EcO83-OMVs) can reduce allergic airway inflammation in mice.
Methods
EcO83-OMVs were isolated by ultracentrifugation and characterised their number, morphology (shape and size), composition (proteins and lipopolysaccharide; LPS), recognition by innate receptors (using transfected HEK293 cells) and immunomodulatory potential (in naïve splenocytes and bone marrow-derived dendritic cells; BMDCs). Their allergy-preventive effect was investigated in a mouse model of ovalbumin-induced allergic airway inflammation.
Results
EcO83-OMVs are spherical nanoparticles with a size of about 110 nm. They contain LPS and protein cargo. We identified a total of 1120 proteins, 136 of which were enriched in OMVs compared to parent bacteria. Proteins from the flagellum dominated. OMVs activated the pattern recognition receptors TLR2/4/5 as well as NOD1 and NOD2. EcO83-OMVs induced the production of pro- and anti-inflammatory cytokines in splenocytes and BMDCs. Intranasal administration of EcO83-OMVs inhibited airway hyperresponsiveness, and decreased airway eosinophilia, Th2 cytokine production and mucus secretion.
Conclusions
We demonstrate for the first time that intranasally administered OMVs from probiotic G- bacteria have an anti-allergic effect. Our study highlights the advantages of OMVs as a safe platform for the prophylactic treatment of allergy.
Publisher
Research Square Platform LLC
Reference71 articles.
1. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?;Akdis CA;Nat Rev Immunol,2021
2. Past, present, and future of allergen immunotherapy vaccines;Dorofeeva Y;Allergy: Eur J Allergy Clin Immunol,2021
3. Mechanisms of allergic disease - environmental and genetic determinants for the development of allergy;Campbell DE;Clin Exp Allergy,2015
4. Microbiome and asthma;Sokolowska M;Asthma Res Pract,2018
5. Influences of environmental bacteria and their metabolites on allergies, asthma, and host microbiota;Jatzlauk G;Allergy: Eur J Allergy Clin Immunol,2017